Shukra Pharmaceuticals Limited shareholders have approved a proposal to change the company's name to Shukra Medtech Limited. The decision was ratified through a postal ballot process, marking a strategic shift in the company's corporate identity.

The voting results, declared on September 29, 2026, confirmed that both proposed resolutions were passed with overwhelming support. The first resolution involved an amendment to the object clause of the Memorandum of Association (MOA), while the second authorized the name change and consequent amendments to the MOA and Articles of Association.

Voting Details and Turnout

The remote e-voting period ran from August 28, 2026, to September 26, 2026. Out of 30,891 shareholders on record as of August 21, 2026, a total of 107,58,652 votes were polled for the first resolution and 84,78,652 votes for the second. The promoters and promoter group participated actively in the e-voting process, casting significant vote shares in favor of both resolutions.

Resolution No. 1: Amendment in Object Clause

This special resolution sought to amend the object clause of the MOA. The promoters voted in favor with 1,02,60,000 votes, while public non-institutional shareholders cast 4,95,536 votes in favor against 3,116 votes against.

Resolution No. 2: Change of Name

The second special resolution approved changing the name from 'Shukra Pharmaceuticals Limited' to 'Shukra Medtech Limited'. Promoters voted in favor with 79,80,000 votes. Public non-institutional shareholders supported the move with 4,95,349 votes, while 3,303 votes were cast against.

What the Numbers Show

The data reveals a stark divergence in shareholder participation between the promoter group and the public. While promoters held 22,48,70,600 shares, they voted only 1,02,60,000 shares for Resolution 1 and 79,80,000 for Resolution 2, indicating selective participation rather than full engagement of their holding. Conversely, public non-institutional shareholders, who held 21,42,28,840 shares, had a much lower turnout, with only roughly 0.23% of their total holdings being voted. This suggests that while the resolutions passed easily due to promoter backing, broader retail investor engagement remained minimal.

Shukra Pharmaceuticals has closed its trading window for dealing in company securities starting October 1, 2026. This closure applies to promoters, directors, key managerial personnel, and connected persons ahead of the declaration of unaudited financial results for the quarter ended September 30, 2026.

The restriction remains in effect until 48 hours after the announcement of the Q2FY27 financial results. The move is pursuant to Clause 4(2) of Schedule B read with Regulation 9 of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Regulatory Compliance and Scope

The closure covers all designated persons, including dependants and immediate relatives as defined in the company's Insider Trading Code. It also extends to connected persons who may have access to unpublished price-sensitive information.

The company cited SEBI Circular No. SEBI/HO/ISD/ISD-SEC-4/P/CIR/2022/107 dated August 5, 2022, and SEBI/HO/ISD/ISD-PoD-2/P/CIR/2023/124 dated July 19, 2023, as the basis for this procedural step. These circulars reinforce the internal procedures for regulating trading by insiders during sensitive periods.

Upcoming Board Meeting

The date for the Board Meeting to approve the unaudited financial results for the quarter ended September 30, 2026, will be announced in due course. Until then, all relevant parties are advised to refrain from entering into any transactions involving the securities of the company.

This standard compliance measure ensures that no insider trading occurs while material financial information is being finalized and prepared for public disclosure.